scholarly journals Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Daphne M. V. Huizing ◽  
Else A. Aalbersberg ◽  
Michelle W. J. Versleijen ◽  
Margot E. T. Tesselaar ◽  
Iris Walraven ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Response Assessment ◽  
Early Response ◽  
Peptide Receptor ◽  
Early Response Assessment

scholarly journals The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1083
Author(s):  
Virginia Liberini ◽  
Martin W. Huellner ◽  
Serena Grimaldi ◽  
Monica Finessi ◽  
Philippe Thuillier ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Response Assessment ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Morphological Response ◽  
Peptide Receptor ◽  
Clinical Biomarkers ◽  
Standardized Parameters

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.

scholarly journals 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1463
Author(s):  
Licia Uccelli ◽  
Alessandra Boschi ◽  
Corrado Cittanti ◽  
Petra Martini ◽  
Stefano Panareo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Preclinical Studies ◽  
Peptide Fragment ◽  
Free Survival ◽  
Peptide Receptor ◽  
Yttrium 90

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin-modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β-emitting radionuclides, such as yttrium-90 and lutetium-177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio-treatment: [90Y]Y-DOTATOC and [177Lu]Lu-DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.

scholarly journals The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

2020 ◽  
Author(s):  
Virginia Liberini ◽  
Martin W. Hüllner ◽  
Serena Grimaldi ◽  
Monica Finessi ◽  
Philippe Thuillier ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Response Assessment ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Morphological Response ◽  
Peptide Receptor ◽  
Clinical Biomarkers ◽  
Standardized Parameters

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owing to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging, and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.

scholarly journals Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

2019 ◽  
Vol 60 (9) ◽  
pp. 1259-1265 ◽  
Author(s):  
Else A. Aalbersberg ◽  
Daphne M.V. Huizing ◽  
Iris Walraven ◽  
Berlinda J. de Wit-van der Veen ◽  
Harshad R. Kulkarni ◽  
...  
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Tratamento de Tumores Neuroendócrinos Gastroenteropancreáticos com 177Lu-DOTA-TATE: Experiência do Instituto Português de Oncologia do Porto

2016 ◽  
Vol 29 (11) ◽  
pp. 726 ◽  
Author(s):  
Inês Lucena Sampaio ◽  
Henrique Vara Luiz ◽  
Liliana Sobral Violante ◽  
Ana Paula Santos ◽  
Luís Antunes ◽  
...  
Keyword(s):  
Overall Survival ◽  
Side Effects ◽  
Radionuclide Therapy ◽  
Liver Toxicity ◽  
Somatostatin Receptors ◽  
Peptide Receptor Radionuclide Therapy ◽  
Symptomatic Improvement ◽  
Hematologic Toxicity ◽  
Safety And Efficacy ◽  
Peptide Receptor

Introduction: The purpose of this article is to report the experience of Instituto Português de Oncologia do Porto in the treatment of gastroenteropancreatic neuroendocrin tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality.Material and Methods: A retrospective analysis of clinical reports of patients with gastrentheropancreatic neuroendocrine tumors undergoing treatment with 177Lu-DOTA-TATE between April 2011 and November 2013 was performed.Results: Thirty six cases were reviewed and 30 completed all 3 cycles of 177Lu-DOTA-TATE (83.3%). In these patients it was registered: acute side effects in 8.9% of cycles; grade 3 CTCAE liver toxicity in 13.3% of patients (all with previous abnormal liver function); absence of significant renal or hematologic toxicity; symptomatic improvement in 71.4% of patients; median overall time to progression of 25.6 months; median overall survival from diagnosis of 121.7 months. Patients with higher expression of somatostatin receptors had longer progression-free survival and overall survival times (p < 0.05).Discussion: Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is an effective, secure and well-tolerated treatment, as evidenced in our study by the following findings: symptomatic improvement in most patients and increased time to disease progression and survival (especially in those with higher sstr expression), with acute and significant subacute/chronic side effects reported only in a minority of cases.Conclusion: Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is a promising treatment for patients with gastrentheropancreatic neuroendocrin tumors, with demonstrated benefits in terms of safety and efficacy.

Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: Initial results of a multiinstitutional cancer registry.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14513-e14513
Author(s):  
Dieter Hörsch ◽  
Keyword(s):  
Overall Survival ◽  
Effective Treatment ◽  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Proliferation Rate ◽  
Primary Tumors ◽  
Peptide Receptor ◽  
Well Differentiated

e14513 Background: Peptide receptor radionuclide therapy is an effective treatment option for patients with well differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies. Methods: We initiated a multi-institutional, prospective and board reviewed registry for patients treated with Peptide receptor radionuclide therapy in Germany in 2009. Results: In five centers, 297 patients were registered. Primary tumors were mainly derived from pancreas (117/297), small intestine (80/297) whereas 56 were of unknown primary. Most tumors were well differentiated with a median Ki67 proliferation rate of 5% (range 0.9 to 70). Peptide receptor radionuclide therapy was performed using mainly Yttrium-90 and/or Lutetium-177 as radionuclides in 1-8 cycles. Mean overall survival was estimated at 213 months with a follow up between 1 and 230 months after initial diagnosis and 87 months with a follow up between 1 and 92 months after start of Peptide receptor radionuclide therapy. Median overall survival was not yet reached. Subgroup analysis demonstrated that best results were obtained in neuroendocrine tumors with a proliferation rate below 20%. Conclusions: Our results indicate that Peptide receptor radionuclide therapy is an effective treatment well and moderately differentiated neuroendocrine tumors irrespective of previous therapies and should be regarded a one of the primary treatment options for patients with neuroendocrine tumors.

Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4113-4113
Author(s):  
Andreja Frilling ◽  
Ashley Clift ◽  
Adil Al-Nahhas ◽  
Richard P. Baum ◽  
Daniel Kaemmerer
Keyword(s):  
Overall Survival ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Initial Diagnosis ◽  
Surgical Morbidity ◽  
Naive Patient ◽  
Free Survival ◽  
Peptide Receptor

4113 Background: Neuroendocrine neoplasia (NEN) of the pancreas (PanNEN) or small bowel (SBNEN) frequently present with metastases at initial diagnosis, undermining the efficacy of surgical treatment. Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, has been shown to achieve prolonged progression-free survival (PFS) and overall survival (OS) in a substantial number of non-surgical patients with advanced NEN. Our aim was to prospectively determine the efficacy of a combination of radical loco-regional surgery and 177Lu PRRT in patients with metastasised NEN. Methods: A set of inclusion criteria was defined (e.g. PanNEN or SBNEN, G1/G2 NEN, initial tumour diagnosis, treatment naïve patient, stage IV NEN, positivity on 68Ga DOTATATE or DOTATOC PET/CT, eligibility for surgery and PRRT). Patients underwent PRRT within 3 months following surgery. Follow-up included biochemistry and imaging. Outcome measures included 1-, 3-, and 5-year OS and PFS from initial diagnosis. Results: Forty-one patients met eligibility criteria and were included. There were 26 males (63.4%) and median age at surgery was 58.8 years (range 32.1-78.3). All patients with SBNEN underwent right hemicolectomy, terminal ileal resection and mesenteric lympadenectomy. In PanNEN patients either Whipple procedure or distal pancreatectomy and peripancreatic lymphadenectomy were performed. The median number of PRRT cycles was 4 (range 2-6). Post-treatment mortality was 0%. Surgical morbidity was 12% (all grade 1 according Clavien-Dindo) and transient grade 1 toxicity occurred post PRRT in 40%. There was no grade 3 toxicity. Median follow-up was 5.48 years (range 0.53 – 11.98). Median PFS and OS were 3.33 years and 9.07 years, respectively. Progression-free survival (with 95% CI) was at 1-, 3-, and 5-years 80% (68.7-92.6), 60.9% (45.9-75.9) and 43.3% (27.4-59.3), respectively. Overall survival (with 95% CI) at 1-, 3-, and 5-years was 97.6% (93-100), 97.6% (93-100), and 95% (87-100), respectively. Conclusions: Radical loco-regional surgery for primary tumours combined with PRRT provides a novel, highly efficacious approach in metastasised NEN.

Sign in / Sign up

Export Citation Format

Share Document